THE LEASE RAN TO 2036. THE TENANT PAID TO LEAVE IN 2026.

THE CASE

Passage Bio entered 2025 with roughly eleven years remaining on a 62,359-square-foot laboratory lease. It stopped using the lab that January. Fourteen months later, it paid approximately $4.8 million plus accrued rent to terminate the lease, extinguishing ten remaining contract years and removing $18.0 million of operating lease liabilities from its balance sheet.

The property did not wait for March 2036 to discover the lease's economic life.

This case exposes a blind spot inside institutional rent rolls. Contractual WALE records the legal term. It cannot show how long a tenant's capital, product strategy, operating model, and facility requirements will continue to support the space. For a pre-revenue biotech tenant, those clocks can move years before lease expiration, rent default, or a visible property-level problem.

Mendria calls the missing measure Economic WALE: the probability-weighted duration of rent and recovery after underwriting the tenant's ability to fund operations, its continuing need for the specific facility, the lease's credit protections, and the owner's reuse options. The investing edge sits inside the gap between the two dates.

WHY THIS CASE MATTERS

The earlier Mendria cases established three timing gaps. Note 04 showed full occupancy persisting while an insurance shock erased financeable NOI. Note 06 showed current data-center revenue persisting while unsecured power reduced the value of the next phase. Note 07 showed lender and buyer terms moving ahead of appraisals and cleanup. Passage adds a fourth gap: contract rent can remain legally alive after the tenant's operating strategy has stopped supporting the space.

The Hopewell lease looked durable on conventional screens:

• A 15-year initial term that began in March 2021 and ran to March 2036.
• A contractual termination option only in March 2032, subject to notice and a fee.
• A purpose-built 62,359-square-foot facility inside the 1.2 million-square-foot Princeton West Innovation Campus.
• Permitted uses spanning laboratory, research and development, process development, non-GMP and commercial GMP manufacturing, warehouse, and pilot-plant activity.
• A public-company tenant with audited SEC financial statements.
• Approximately $76.8 million of cash, cash equivalents, and marketable securities at year-end 2024.

The operating evidence pointed elsewhere. Passage had narrowed its pipeline, transferred three pediatric gene-therapy programs to another company, begun subleasing lab space, impaired the Hopewell asset group, shifted analytical testing to outside providers, stopped lab operations, and sold substantially all laboratory equipment.

Those signals changed the facility's role inside the tenant before they changed the lease document.

That distinction matters across life-science portfolios. A clinical-stage company can retain cash and continue paying rent after the space has lost its strategic purpose. A company with a short disclosed runway can also raise capital, sign a partnership, or advance a program and remain a durable occupant. Cash runway alone produces too many false alarms. The price signal emerges from the interaction of capital capacity, program continuation, facility necessity, lease recovery, and reuse value.

THE ASSET THE TENANT THOUGHT IT NEEDED

Passage announced the Hopewell laboratory in December 2020 as a key part of an integrated gene-therapy manufacturing supply chain. The facility would support analytics, process development, quality control, pilot manufacturing, assay development and validation, biomarker testing, and clinical product testing. The company expected more than 20 new positions at the lab and described internal CMC capability as a source of control over vector manufacturing and product quality.

The lease matched that ambition. It covered portions of Building 21 at 311 Pennington Rocky Hill Road and included laboratory, annex, office, and storage areas. Certain lab areas required at least eight air changes per hour and 100% outside air. The campus supplied central utilities, wastewater infrastructure, conference facilities, and expansion options. The lease allowed Passage to use the premises for R&D through commercial GMP manufacturing.

The original public filing estimated approximately $40.3 million of rent payments over the initial term. The company had a one-time contractual right to exit after the twelfth lease year. That future option required payment of unamortized transaction costs, including tenant improvement allowance, free rent, legal fees, planning costs, and brokerage fees, plus 7% interest and three months of then-current base rent.

The 2026 termination followed a separately negotiated path, roughly six years before that option date.

One lease provision makes the case especially instructive. Section 47 expressly acknowledged that Passage's audited financial statements were publicly available through SEC filings. It also allowed the landlord to request additional financial information in connection with a sale or refinancing. Section 18 listed the security deposit as “Intentionally Deleted.” The landlord's forward credit view therefore depended heavily on Passage's corporate capacity, lease remedies, operating trajectory, and the value of the space upon recovery.

The data existed. The missing layer was the conversion from biotech events into property cash flow.

THE TIMELINE THE RENT ROLL COULD NOT SHOW

The sequence contains the critical insight. The lease termination was signed on March 4. The FDA update arrived on April 20. The dates rule out the April regulatory decision as the trigger for the Hopewell exit.

By the time the headline corporate setback arrived, the real-estate decision had already been made.

Mendria's signal would have formed from the program transfer, sublease, impairment, outsourcing decision, lab closure, equipment disposal, and market-recovery assumptions. A model waiting for a failed trial, a going-concern disclosure, or a missed rent payment would have entered after the property event.

FOUR CLOCKS INSIDE ONE LEASE

A life-science lease carries at least four independent clocks:

1. Contract clock

The legal expiration, break option, renewal rights, assignment and sublease terms, default remedies, guarantees, deposits, letters of credit, and termination economics.

For Passage: March 2036 expiration, a March 2032 termination option, sublease rights subject to landlord controls, no stated security deposit, and public financial reporting.

2. Capital clock

The period funded by unrestricted cash, marketable securities, committed collaboration payments, borrowing capacity, remaining ATM capacity, and credible access to new equity.

For a pre-revenue biotech, rent is financed by capital markets and strategic payments. EBITDA coverage provides little help.

3. Program clock

The next clinical readout, regulatory meeting, enrollment decision, partnership payment, manufacturing transfer, program stop, or portfolio-prioritization event that changes how much space the company needs.

For Passage: the July 2024 program transfer and termination of preclinical discovery obligations narrowed the work requiring internal infrastructure.

4. Space clock

The remaining period during which this exact suite supports the tenant's operating model. Internal versus outsourced testing, headcount by function, equipment presence, sublease marketing, fit-out utilization, and manufacturing strategy all move this clock.

For Passage: outsourced analytics and the January 2025 shutdown ended operating use roughly eleven years before contractual expiry.

Traditional WALE reads Clock 1. A tenant-derived forward rent roll fuses all four.

ECONOMIC WALE

Economic WALE measures the expected duration of current-lease cash flow and recovery in current-rent-equivalent years.

For tenant i:

Each future rent payment is probability-weighted. Exit recovery includes expected termination payments, letters of credit, deposits, guarantees, and other recoveries attributable to the current lease. Replacement NOI sits in the asset NPV as a separate path, preventing double counting. The probability weights reflect:

• Payment capacity: liquidity, adjusted burn, financing access, partnership receipts, debt, and market capitalization.
• Program continuation: clinical and regulatory milestones, portfolio concentration, program discontinuations, and partner behavior.
• Facility necessity: internal manufacturing or testing strategy, headcount by function, equipment, utilization, outsourcing, and sublease activity.
• Contract recovery: guarantee, letter of credit, deposit, termination fee, remedies, assignment, sublease, and landlord recapture rights.
• Space recovery: downtime, divisibility, fit-out portability, infrastructure, market rent, concessions, tenant improvements, commissions, and alternative-use value.

The same tenant can have zero operational occupancy and positive recovery value. Passage stopped using Hopewell in January 2025, continued carrying the lease, and later paid a negotiated fee. A model that equates an empty lab with immediate lost rent will also misprice the asset.

That produces a three-line forward rent roll plus a separate property-recovery case:

Economic WALE is the probability-weighted bridge across those three lines.

WHY CASH RUNWAY ALONE FAILS

The easy version of this analysis ranks tenants by cash divided by quarterly burn. That screen can identify attention candidates. It cannot price a lease.

Passage illustrates both errors a cash-only model can make.

At December 31, 2024, Passage held approximately $76.8 million of cash, cash equivalents, and marketable securities. The company publicly projected that restructuring and outsourcing would extend its runway into the first quarter of 2027. A simple credit view could still treat the 2036 rent as collectable for a meaningful period.

At the same time, the lab had lost its strategic role. Passage had transferred programs, begun subleasing Hopewell space, taken a $5.2 million impairment, outsourced testing, ceased lab operations, and prepared to sell the equipment. The company could pay while having no reason to occupy.

The opposite fact pattern also occurs. A tenant with twelve months of disclosed runway may own a valuable late-stage program, maintain a live ATM, attract partnership capital, and occupy a scarce GMP suite that remains essential through every financing scenario. Short runway can coexist with durable facility need and strong recovery.

Mendria therefore separates two probabilities:

• Probability the company remains funded.
• Probability this facility remains necessary under the funded strategy.

Their interaction determines the rent hazard. Credit support and reuse determine the loss given exit.

THE FIRST COUNTERPARTY TO SEE IT

In this case, the tenant's own operating and accounting records carried the signal first.

The 2024 impairment translated sublease cash flows and residual-period assumptions into a reduced asset value. The January 2025 restructuring translated strategy into zero lab use. The December 2025 impairment explicitly incorporated rental-market activity and a market-participant subtenant borrowing rate. KPMG identified the 2025 Hopewell impairment analysis as a critical audit matter because sublease market activity and discount-rate assumptions required significant judgment.

That audit trail is a shadow property valuation. It appears in the tenant's filing, outside the owner's rent roll, and can lead the property appraisal.

The conversion then travels through real-estate counterparties:

The tenant and auditor observe the facility-use change. The landlord prices the exit. The property's lender, appraiser, and next buyer price the quality and duration of the replacement cash flow.

THE $4.8 MILLION WALK-AWAY PRICE

The March 2026 settlement creates a rare public price point.

Passage paid approximately $4.8 million plus accrued rent through February 14, 2026. It had no further obligations after the termination. The transaction removed $18.0 million of operating lease liabilities and $9.4 million of right-of-use assets. Passage also recorded a $3.2 million loss on disposed property and equipment, primarily leasehold improvements, offset by a $3.8 million gain from writing off lease assets and liabilities. The net accounting gain was $0.6 million.

The $18.0 million liability is an accounting present value. Treating the $13.2 million difference as a disclosed landlord loss would be wrong. The settlement also returned possession and control of the suite, ended the 3,200-square-foot sublease concurrently, and reset the owner's ability to lease, divide, reposition, or repurpose the space. The public record gives no landlord leasing pipeline, capital basis, debt structure, or post-termination rent. It cannot support a judgment about which side captured more value.

It can support the correct investment calculation.

The owner compares two strategies:

A negotiated exit creates value when V_exit > V_hold. The minimum acceptable fee is the amount that closes the gap after the owner prices early control of the space.

This is lease-exit arbitrage. A tenant with remaining cash can pay for relief. An owner with a viable replacement plan can monetize control before the tenant's credit deteriorates further. Delay reduces the tenant's ability to fund a settlement and shortens the owner's leasing window before a refinance or sale.

HOW MANY DOLLARS WERE EXPOSED

The public case supplies four hard figures:

The original $40.3 million schedule averages approximately $2.69 million per year, or $43.08 per square foot per year, across the initial 15-year term. This simple average is used only as a disclosed contract sensitivity. Calculating 2026 passing rent and property NOI requires separate data.

That average provides a transparent reletting sensitivity:

On that average-rent basis, the $4.8 million fee equaled approximately $77 per square foot and 21 months of gross scheduled rent. A two-year rent gap would exceed the fee before brokerage, free rent, tenant improvements, operating carry, or any difference in replacement rent. A fast re-lease with reusable infrastructure could produce a far better result.

A 24-month gap plus $50 to $150 per square foot of new leasing capital produces an $8.5 million to $14.7 million gross reset budget before commissions and concessions. Applying the disclosed $4.8 million fee reduces that simple range to $3.7 million to $9.9 million before accrued rent, operating carry, replacement-rent differences, and the value of retained infrastructure. Debt proceeds and permanent NOI changes can move the total asset-value exposure higher. Mendria would calculate the property-specific amount from the rent roll, debt, operating expenses, market leasing terms, fit-out condition, and live tenant pipeline.

THE MARKET MADE RECOVERY MORE PATH-DEPENDENT

Passage's exit landed during a severe lab-space reset.

CBRE reported record U.S. lab/R&D vacancy of 23.8% in the second quarter of 2026 and an 8.1% year-over-year decline in asking rents. JLL reported that national lab availability had begun to contract by June 2026, while substantial oversupply and rent pressure remained. More than 6.2 million square feet had already moved out of lab inventory into other asset classes, and JLL estimated a national supply-to-demand ratio near 6:1.

Those figures cannot price Building 21. They change the distribution of outcomes.

Recovery depends on the suite's exact capabilities and the replacement demand it can serve:

• Wet lab, analytical lab, pilot manufacturing, GMP, office, and storage proportions.
• Air changes, outside-air capacity, backup systems, floor loads, wastewater, utilities, loading, and hazardous-material permissions.
• Validation status, clean-room classification, equipment ownership, and the portability of prior improvements.
• Ability to divide the suite without destroying infrastructure efficiency.
• Cluster depth, talent access, transit, and proximity to research institutions.
• Demand from biotech, pharma, diagnostics, advanced manufacturing, robotics, AI-enabled science, and tough-tech users.

JLL's 2026 research also shows a sharp flight to quality. Buildings completed since 2020 reduced availability by 2.6 million square feet over nine months while pre-2000 inventory added 700,000 square feet. That pattern rewards assets with flexible, current, counterparty-ready infrastructure and penalizes obsolete or over-specialized buildouts.

The underwriting question reaches beyond “How much lab space is vacant?” It asks: How many funded replacement users can occupy this exact suite, by the owner's capital-event date, after the owner spends the required dollars?

THE TENANT-DERIVED FORWARD RENT ROLL

Mendria would screen every material life-science tenant across seven layers:

The portfolio output includes:

• Contractual WALE.
• Break-adjusted WALE.
• Operational WALE.
• Economic WALE.
• Probability-adjusted rent by quarter.
• Expected lease-exit payment and recovery range.
• Expected downtime, TI, concessions, and commissions.
• Fit-out reuse value and alternative-use optionality.
• Lender and buyer downside case.
• Recommended owner action, cost, and last responsible date.

A 2036 expiration can remain in the legal column while the forward rent roll starts de-risking the cash flow in 2024.

THE ACQUISITION EDGE

The same model finds overpriced income and underpriced recovery.

Trade 1: Refuse to pay for nominal WALE

An acquisition model capitalizes a ten-year biotech lease as durable income. Mendria sees a tenant with narrowing programs, falling facility need, weak credit support, a sublease signal, and a property loan maturing inside the tenant's funding horizon. The buyer removes part of the rent tail, adds downtime and leasing capital, and bids to a probability-adjusted basis before the lease changes publicly.

Trade 2: Buy the recovery others cannot underwrite

A market applies a broad discount to a building with biotech rollover. Mendria finds a divisible suite, reusable infrastructure, funded replacement demand, a tenant able to pay a negotiated exit fee, and enough time before debt maturity to execute. The buyer prices the cure separately from the headline risk and acquires below replacement-adjusted value.

Trade 3: Negotiate control while the tenant still has cash

The owner compares expected lease enforcement with a consensual surrender. A funded tenant can pay for relief, transfer useful improvements, preserve permits and data, coordinate subtenant treatment, and provide early access for tours and construction. The owner gains time. The tenant gains certainty. The value comes from executing before liquidity pressure hardens each side's alternatives.

Passage's $4.8 million settlement demonstrates that the lease tail itself can become a tradable claim. The investor with the better model of recovery can price that claim before the next lender or buyer does.

THE ACTION WINDOW

The highest-value intervention may be a lease amendment, a larger LC, a direct lease with the subtenant, an early surrender, a subdivision, a conversion, or a decision to hold the tenant to the contract. Mendria ranks the options by expected asset value after cost and time.

WHAT AN OWNER COULD HAVE KNOWN

This retrospective should remain disciplined. Public evidence cannot reveal the landlord's internal awareness, negotiation start date, debt terms, leasing pipeline, or final investment return. The March 2026 agreement may reflect a well-timed recovery strategy that began long before disclosure.

The case proves a narrower claim:

• Public tenant events materially changed facility necessity before the lease term changed.
• The tenant's own impairment analysis reflected sublease and rental-market economics before formal termination.
• Operations ended fourteen months before the lease exit.
• A negotiated payment converted ten remaining contract years into current cash and returned control.
• The decisive real-estate chronology preceded the later FDA setback and going-concern disclosure.

An owner, lender, or buyer with a tenant-derived forward rent roll could have modeled the reset before March 2026. The action would still require judgment. The signal was available.

MODEL DISCIPLINE

Life-science tenant monitoring can easily become a list of dramatic headlines. Mendria applies four controls:

Facility specificity

A failed program matters only to the facilities that support it. The model maps program, function, vendor, equipment, and location before changing rent probability.

Financing reflexivity

Runway can lengthen through equity, partnerships, milestones, cost reductions, or asset sales. Financing capacity updates continuously. A static cash-burn division cannot grade the lease.

Contract recovery

Physical vacancy and lost rent occur on different dates. Guarantees, LCs, deposits, termination payments, subleases, and bankruptcy recoveries change loss severity.

Space optionality

Returned control can carry material value. A flexible, infrastructure-rich suite inside a deep cluster can outperform the expiring lease. A highly customized suite in an oversupplied secondary node can produce a long and expensive recovery.

A signal earns a pricing adjustment only when it changes expected rent, recovery, downtime, capital, proceeds, or exit value.

WHY EXISTING WORKFLOWS MISS THE WINDOW

The lease abstract belongs to asset management. Clinical catalysts sit with biotech analysts. Cash and ATM capacity sit in SEC filings. Equipment and outsourcing decisions sit in operating releases. Sublease terms sit in footnotes and brokerage markets. The impairment model sits in the tenant's audited accounts. Property debt maturity sits with the capital-markets team.

Each source describes one clock. The asset reprices when the clocks collide.

The Passage lease included the financial-information rights needed to monitor credit. The public record disclosed the capital, program, footprint, lease, and impairment signals. Manual review still requires an analyst to reconstruct the operating strategy, connect it to one exact suite, estimate settlement and reletting economics, then align the result with the property's next financing or sale.

That is the repricing graph at work:

THE INVESTING EDGE

A ten-year rent roll can contain eighteen months of economic certainty. A short-runway tenant can contain a valuable lease recovery. The rent roll alone cannot tell them apart.

Mendria models the next counterparty's version of the cash flow:

• The lender asks how much of in-place rent deserves credit through maturity.
• The buyer asks what it will cost and how long it will take to replace the tenant.
• The appraiser asks whether contract rent remains representative of market participant expectations.
• The owner asks whether a fee and early control exceed the expected value of holding the lease.

Passage Bio gave the market an unusually clean record. A lease scheduled through March 2036 lost its operating purpose in January 2025. The tenant paid $4.8 million to exit in March 2026. The company removed $18.0 million of lease liabilities. The later corporate crisis arrived after the real-estate transaction.

The conventional model would update the rent roll when the termination became effective. The investing edge was available when the tenant's pipeline stopped supporting the space.